Given the median survival of 15 months after diagnosis, novel treatment strategies are needed for glioblastoma. Beta-blockers have been demonstrated to inhibit angiogenesis and tumor cell proliferation in various cancer types. The aim of this study was to systematically review the evidence on the effect of beta-blockers on glioma growth. A systematic literature search was performed in the PubMed, Embase, Google Scholar, Web of Science, and Cochrane Central to identify all relevant studies. Preclinical studies concerning the pharmacodynamic effects of beta-blockers on glioma growth and proliferation were included, as well as clinical studies that studied the effect of beta-blockers on patient outcomes according to PRISMA guidelines. Among the 980 citations, 10 preclinical studies and 1 clinical study were included after title/abstract and full-text screening. The following potential mechanisms were identified: reduction of glioma cell proliferation (n = 9), decrease of glioma cell migration (n = 2), increase of drug sensitivity (n = 1), induction of glioma cell death (n = 1). Beta-blockers affect glioma proliferation by inducing a brief reduction of cAMP and a temporary cell cycle arrest in vitro. Contrasting results were observed concerning glioma cell migration. The identified clinical study did not find an association between beta-blockers and survival in glioma patients. Although preclinical studies provide scarce evidence for the use of beta-blockers in glioma, they identified potential pathways for targeting glioma. Future studies are needed to clarify the effect of beta-blockers on clinical endpoints including survival outcomes in glioma patients to scrutinize the value of beta-blockers in glioma care.

鉴于诊断后 15 个月的中位生存期，胶质母细胞瘤需要新的治疗策略。β-受体阻滞剂已被证明可抑制各种癌症类型的血管生成和肿瘤细胞增殖。本研究的目的是系统地审查有关 β 受体阻滞剂对神经胶质瘤生长影响的证据。在 PubMed、Embase、Google Scholar、Web of Science 和 Cochrane Central 中进行了系统的文献检索，以确定所有相关研究。包括关于 β 受体阻滞剂对神经胶质瘤生长和增殖的药效学影响的临床前研究，以及根据 PRISMA 指南研究 β 受体阻滞剂对患者预后影响的临床研究。在 980 篇引文中，10 项临床前研究和 1 项临床研究在标题/摘要和全文筛选后被纳入。确定了以下潜在机制：减少胶质瘤细胞增殖（n  = 9)，神经胶质瘤细胞迁移减少 ( n  = 2)，药物敏感性增加 ( n  = 1)，诱导神经胶质瘤细胞死亡 ( n  = 1)。β 受体阻滞剂通过在体外诱导短暂的 cAMP 减少和暂时的细胞周期停滞来影响神经胶质瘤的增殖。观察到关于神经胶质瘤细胞迁移的对比结果。确定的临床研究未发现 β 受体阻滞剂与胶质瘤患者的生存率之间存在关联。尽管临床前研究为在胶质瘤中使用 β 受体阻滞剂提供了很少的证据，但他们确定了靶向胶质瘤的潜在途径。未来的研究需要阐明 β 受体阻滞剂对临床终点的影响，包括胶质瘤患者的生存结果，以审查 β 受体阻滞剂在胶质瘤治疗中的价值。